ConductScience.org, home

Paper55060

Effects of long-term treatment with procaine amide. A prospective study with special regard to ANF and SLE in fast and slow acetylators.

Henningsen NC and 3 others. Acta Med Scand, 1975. Cited by 114 papers, by iCite.

Cite this record

ConductScience Library. Effects of long-term treatment with procaine amide. A prospective study with special regard to ANF and SLE in fast and slow acetylators. Papers, record 55060. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/55060

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of long-term treatment with procaine amide. A prospective study with special regard to ANF and SLE in fast and slow acetylators.
PubMed
Journal
Acta Med Scand
PubMed
Year
1975
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
114
iCite
Relative citation ratio, by iCite
5.4
iCite
Revised in PubMed
2013-11-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Henningsen NCN C
2Cederberg AA
3Hanson AA
4Johansson BWB W

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, AntinuclearMajor topic
Arrhythmias, CardiacMajor topic
Lupus Erythematosus, SystemicMajor topic
NeutrophilsMajor topic
ProcainamideMajor topic
Acetylation
Adult
Aged
Female
Humans
Male
Middle Aged
Phenotype
Sulfanilamides
Time Factors

Source PubMed

Download CSV of topics

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 114 citations.

PMIDTitleJournalYearIn PapersSource
30878168Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation.J Autoimmun2019https://conductscience.org/library/papers/30878168PubMed
22387617Metabolomics reveals the metabolic map of procainamide in humans and mice.Biochem Pharmacol2012https://conductscience.org/library/papers/22387617PubMed
20544243Acrylamine-induced autoimmune phenomena.Clin Rheumatol2010https://conductscience.org/library/papers/20544243PubMed
9773259Anti-DNA, antihistone, and antinucleosome antibodies in systemic lupus erythematosus and drug-induced lupus.Clin Rev Allergy Immunol1998https://conductscience.org/library/papers/9773259PubMed
9291752Betaxolol and drug-induced lupus complicated by pericarditis and large pericardial effusion.West J Med1997https://conductscience.org/library/papers/9291752PubMed
8103355Clinical significance of genetic influences on cardiovascular drug metabolism.Cardiovasc Drugs Ther1993https://conductscience.org/library/papers/8103355PubMed
7011656Acetylator phenotype and lupus erythematosus.Clin Pharmacokinet1981https://conductscience.org/library/papers/7011656PubMed
6887275Low-dose procainamide: low risk of complications with long-term use.J Natl Med Assoc1983https://conductscience.org/library/papers/6887275PubMed
6759093Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.Drugs1982https://conductscience.org/library/papers/6759093PubMed
6217216Immunomodulatory effect of procainamide in man. Inhibition of human suppressor T-cell activity in vitro.J Clin Invest1983https://conductscience.org/library/papers/6217216PubMed
6198178Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.Eur J Clin Pharmacol1983https://conductscience.org/library/papers/6198178PubMed
6103797Antinuclear antibodies and cardiovascular drugs.Drugs1980https://conductscience.org/library/papers/6103797PubMed
3758143Evaluation of once daily endralazine in hypertension.Eur J Clin Pharmacol1986https://conductscience.org/library/papers/3758143PubMed
2285495Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.Drug Saf1990https://conductscience.org/library/papers/2285495PubMed
1879095Ethnic differences in drug disposition and responsiveness.Clin Pharmacokinet1991https://conductscience.org/library/papers/1879095PubMed
1793523Drug-related lupus. Incidence, mechanisms and clinical implications.Drug Saf1991https://conductscience.org/library/papers/1793523PubMed
911602Acebutolol metabolite plasma concentration during chronic oral therapy.Br J Clin Pharmacol1977https://conductscience.org/library/papers/911602PubMed
648399Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.Drugs1978https://conductscience.org/library/papers/648399PubMed
497093A pharmacokinetic comparison of two sustained-release oral procainamide preparations.Br J Clin Pharmacol1979https://conductscience.org/library/papers/497093PubMed
458558Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.J Pharmacokinet Biopharm1979https://conductscience.org/library/papers/458558PubMed

See all 23 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
NPPA4878PubTator's text mininghttps://conductscience.org/library/genes/4878

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/55060

GET https://conductscience.org/api/papers/v1/55060/cited_by?page=2